[Toxicological evaluation criteria (secondary action aspects)].
D000890:Anti-Infective Agents / Q000009:adverse effects*; D002511:Cephalosporins / Q000009:adverse effects; D002701:Chloramphenicol / Q000009:adverse effects; D004917:Erythromycin / Q000009:adverse effects; D004977:Ethambutol / Q000009:adverse effects; D005839:Gentamicins / Q000009:adverse effects; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008034:Lincomycin / Q000009:adverse effects; D009268:Nalidixic Acid / Q000009:adverse effects; D009355:Neomycin / Q000009:adverse effects; D009582:Nitrofurantoin / Q000009:adverse effects; D010406:Penicillins / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D013307:Streptomycin / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013754:Tetracyclines / Q000009:adverse effects
D000890:Anti-Infective Agents; D002511:Cephalosporins; D005839:Gentamicins; D010406:Penicillins; D013449:Sulfonamides; D013754:Tetracyclines; D009268:Nalidixic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D004977:Ethambutol; D009582:Nitrofurantoin; D008034:Lincomycin; D009355:Neomycin; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Toxikologische Beurteilungskriterien (Nebenwirkungsaspekte).